The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score
Open accessAbstract
Background: The GALAD score is a serum biomarker–based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. Methods: A single-center cohort of 111 HCC patients and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN) phase II HCC Study were analyzed. Results: The area under the ROC curve (AUC) of the GALAD score for HCC detection was 0.95 [95% confidence interval (CI), 0.93–97], which was higher than the AUC of ultrasound (0.82, P <0.01). At a cutoff of −0.76, the GALAD score had a sensitivity of 91% and a specificity of 85% for HCC detection. The AUC of the GALAD score for early-stage HCC detection remained high at 0.92 (95% CI, 0.88–0.96; cutoff −1.18, sensitivity 92%, specificity 79%). The AUC of the GALAD score for HCC detection was 0.88 (95% CI, 0.85–0.91) in the EDRN cohort. The combination of GALAD and ultrasound (GALADUS score) further improved the performance of the GALAD score in the single-center cohort, achieving an AUC of 0.98 (95% CI, 0.96–0.99; cutoff −0.18, sensitivity 95%, specificity 91%). Conclusions: The performance of the GALAD score was superior to ultrasound for HCC detection. The GALADUS score further enhanced the performance of the GALAD score. Impact: The GALAD score was validated in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Singal, A. G., Pillai, A., & Tiro, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001624 · Cited by 817
Atiq, O., Tiro, J., Yopp, A. C., Muffler, A., Marrero, J. A., Parikh, N. D., Murphy, C., McCallister, K., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28895 · Cited by 266
Self-citation
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Self-citationHepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Management of Hepatocellular Carcinoma: A Review
Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 763
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Advances in the Early Diagnosis of Hepatocellular Carcinoma
Wang, W., & Wei, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.014 · Cited by 492
Metadata
- Authors
- Yang, J. D., Addissie, B. D., Mara, K. C., Harmsen, W. S., Dai, J., Zhang, N., Wongjarupong, N., Ali, H. M., Ali, H. A., Hassan, F. A., Lavu, S., Cvinar, J. L., Giama, N. H., Moser, C. D., Miyabe, K., Allotey, L. K., Algeciras-Schimnich, A., Theobald, J. P., Ward, M. M., Nguyen, M. H., Befeler, A. S., Reddy, K. R., Schwartz, M., Harnois, D. M., Yamada, H., Srivastava, S., Rinaudo, J. A., Gores, G. J., Feng, Z., Marrero, J. A., & Roberts, L. R.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2019-03-01
- Volume
- 28
- Issue
- 3
- Pages
- 531-538
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2901770926
- Cited by
- 222
- References
- 5
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. https://app.cochat.ai/papers/10.1158/1055-9965.epi-18-0281
- The paper
- Yang, J. D., Addissie, B. D., Mara, K. C., Harmsen, W. S., Dai, J., Zhang, N., Wongjarupong, N., Ali, H. M., Ali, H. A., Hassan, F. A., Lavu, S., Cvinar, J. L., Giama, N. H., Moser, C. D., Miyabe, K., Allotey, L. K., Algeciras-Schimnich, A., Theobald, J. P., Ward, M. M., . . . Roberts, L. R. (2019). GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-18-0281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.